CURNA is engaged in the discovery of new drugs for the treatment of illnesses such as cancer, heart disease, metabolic disorders and genetic anomalies.

Its broad platform technology is based on the up-regulation of protein production versus the established down-regulate protein production approach. The company has designed and exclusively licensed a novel therapeutic modality termed AntagoNAT, the approach to which has been validated for up-regulation of several therapeutically relevant proteins.

OPKO Chairman and CEO Phillip Frost said the CURNA’s technology may be important for treating diseases such as heart and genetic diseases where increased levels of specific proteins are important.